Apixaban for the prevention of venous thromboembolism in people ...

More documents

Recommendations

Info

Source of funding: This report was commissioned by the NIHR HTA Programme as project number xxxxx STA. Declared competing interests of the authors None. Acknowledgements Professor Stansby, Professor of Vascular Surgery, School of Surgical & Reproductive Sciences, Faculty of Medical sciences, Newcastle University, Newcastle upon Tyne and Co-ordinating Editor of the Cochrane Peripheral Vascular Diseases group, provided advice and commented on the background section of this report. Dr. A. Ten Cate – Hoek, Department of Internal Medicine. Maastricht University Medical Center, Maastricht, the Netherlands, provided advice and commented on the model structure and inputs. Rider on responsibility for report The views expressed in this report are those of the authors and not necessarily those of the NIHR HTA Programme. Any errors are the responsibility of the authors. This report should be referenced as follows: Riemsma R, Joore M, Grutters J, Armstrong N, Misso K, Noake C, Tushabe DA, Deshpande S, Severens JL, Kleijnen J. Apixaban for the prevention of venous thromboembolism in people undergoing elective knee and hip replacement surgery: a Single Technology Appraisal. York: Kleijnen Systematic Reviews Ltd., 2011. Contributions of authors Rob Riemsma acted as project lead and systematic reviewer on this assessment, critiqued the clinical effectiveness methods and evidence and contributed to the writing of the report. Manuela Joore acted as health economic project lead, critiqued the manufacturer’s economic evaluation and contributed to the writing of the report. Janneke Grutters acted as health economist on this assessment, critiqued the manufacturer’s economic evaluation and contributed to the writing of the report. Nigel Armstrong acted as health economist on this assessment, critiqued the manufacturer’s submission and contributed to the writing of the report. Kate Misso and Caro Noake critiqued the search methods in the submission and contributed to the writing of the report. Doreen Allen Tushabe and Sohan Deshpande acted as systematic reviewers, critiqued the clinical effectiveness methods and evidence and contributed to the writing of the report. Johan L. Severens critiqued the manufacturer’s definition of the decision problem and their description of the underlying health problem and current service provision, contributed to the writing of the report and supervised the health economic sections of the report. Jos Kleijnen critiqued the manufacturer’s definition of the decision problem and their description of the underlying health problem and current service provision, contributed to the writing of the report and supervised the project. 2 Copyright 2011 Queen’s Printer and Controller of HMSO. All rights reserved.
Abbreviations AAOS American Academy of Orthopedic Surgeons ACC American College of Cardiology ACCP American College of Chest Physicians AE Adverse Events AIDS Acquired Immune Deficiency Syndrome ASH American Society of Hematology bd/b.i.d Twice Daily BOA British Orthopaedic Association BSH British Society of Haematology CC Complications and Co-morbidities CE Cost Effectiveness CEA Cost-effectiveness Analysis CEAC Cost effectiveness Acceptability Curve CI Confidence Interval CRD Centre for Reviews and Dissemination CRNM Clinically Relevant non Major CTPA Computerised Tomography Pulmonary Angiograph DBG Dabigatran Etexilate DVT Deep Vein Thrombosis EFFORT European Federation of National Associations of Orthopedics and Traumatology EHS European Hematology Society EMEA European Medicines Agency EORS European Orthopedic Research Society ERG Evidence Review Group EUR Erasmus University Rotterdam FID Foot Impulse Device GCS Graduated Elastic Compression Stockings HIT Heparin-induced Thrombocytopenia HRG Health Resource Group HRQL Health-related Quality of Life HTA Health Technology Assessment IC Indirect Comparison ICER Incremental Cost-effectiveness Ratio ICH Intracranial haemorrhage ICMJE International Committee of Medical Journal Editors ICT International Congress on Thrombosis iHEA International Health Economics Association IPCD Intermittent Pneumatic Compression Device ISPOR International Society for Pharmacoeconomics and Outcomes Research ISTH International Society on Thrombosis and Haemostasis ITT Intention to Treat KSR Kleijnen Systematic Reviews LMWHs Low Molecular Weight Heparins LYS Life Year Saved mg Milligram MS Manufacturer’s Submission MTC Mixed Treatment Comparison NCC-AC National Collaborating Centre for Acute Care NHS National Health Services NICE National Institute for Health and Clinical Excellence NIHR National Institute for Health Research NOAC New Oral Anticoagulant NR Not Reported od Once Daily 3 Copyright 2011 Queen’s Printer and Controller of HMSO. All rights reserved.
Page 1: in collaboration with: Apixaban for
Page 5 and 6: 1. SUMMARY ........................
Page 7 and 8: 1. SUMMARY 1.1 Scope of the manufac
Page 9 and 10: The three identified trials, which
Page 11 and 12: Table 2.1. Summary of Annual TKR an
Page 13 and 14: The NICE clinical guideline on redu
Page 15 and 16: Indirect and mixed treatment compar
Page 17 and 18: 4.1.2 State the inclusion/exclusion
Page 19 and 20: APROPOS 2 0 Phase II, randomised, e
Page 21 and 22: 4.2 Summary and critique of submitt
Page 23 and 24: Table 4.5: Results for Apixaban ver
Page 25 and 26: Trial no. (acronym) ADVANCE 1 ADVAN
Page 27 and 28: 4.2.4 Describe and critique the man
Page 29 and 30: Table 4.9: Results from indirect co
Page 31 and 32: Results for the main outcomes from
Page 33 and 34: 5 COST EFFECTIVENESS 5.1 ERG commen
Page 35 and 36: Table 5.1 Main findings of studies
Page 37 and 38: 5.2.2 Model structure The manufactu
Page 39 and 40: died in the decision tree enter the
Page 41 and 42: Administration of apixaban is oral,
Page 43 and 44: A mixed treatment comparison (MTC)
Page 45 and 46: Long term recurrent risks of VTE an
Page 47 and 48: 5.2.7 Health related quality of lif
Page 49 and 50: on assumptions, and not further jus
Page 51 and 52: Table 5.12 Costs for health states
Page 53 and 54:
Table 5.14 Drug and administration
Page 55 and 56:
Comment - The ERG restructured the
Page 57 and 58:
5.2.10 Sensitivity analyses Methods
Page 59 and 60:
Figure 5.3 Cost-effectiveness accep
Page 61 and 62:
Figure 5.6 Cost-effectiveness accep
Page 63 and 64:
Cost-Effectiveness Acceptability Cu
Page 65 and 66:
Cost-Effectiveness Acceptability Cu
Page 67 and 68:
number of QALYs gained by dabigatra
Page 69 and 70:
5.4 Conclusions Describe the comple
Page 71 and 72:
References [1] White RH. The epidem
Page 73 and 74:
[23] Eriksson BI, Dahl OE, Rosenche
Page 75 and 76:
ISPOR 11th Annual European Congress
Page 77 and 78:
Appendix 1A: ERG Search Strategies
Page 79 and 80:
85 84 not 83 (88613) 86 1 or 2 or 3
Page 81 and 82:
76 Comment/ (451657) 77 Letter/ (72
Page 83 and 84:
68 Motion Therapy, Continuous Passi
Page 85 and 86:
23 pentasaccharide*.mp. (2192) 24 e
Page 87 and 88:
Appendix 1B: Review of search strat
Page 89 and 90:
Question(s) Appendix 2: Phillips et
Page 91 and 92:
Has the source for all costs been d
show all

Apixaban for the prevention of venous thromboembolism in people ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?